Welcome to our dedicated page for EDAP TMS SA news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on EDAP TMS SA stock.
EDAP TMS SA (NASDAQ: EDAP) is a global leader in therapeutic ultrasound with over 30 years of experience. The company develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology using advanced ultrasound technology. With a robust presence worldwide through a network of corporate offices, subsidiaries, and distribution partners, EDAP TMS is committed to innovation and excellence.
EDAP TMS operates through three main divisions:
- HIFU (High-Intensity Focused Ultrasound): This division focuses on the development and marketing of devices for the non-invasive destruction of tumors. Key products include Ablatherm, Ablatherm Fusion, and the Focal One, which is the latest addition designed for ideal focal therapy of localized prostate cancer.
- ESWL (Extracorporeal ShockWave Lithotripsy): This division manufactures and services the Sonolith range of lithotripters, which are used for the treatment of kidney stones.
- Distribution: This division markets complementary products such as lasers, micro-ultrasound systems, and other medical devices from third-party suppliers.
EDAP TMS is known for its strong patent portfolio thanks to continuous investment in research and development. The company collaborates with globally acclaimed medical research institutions to push the boundaries of medical technology. Financially, EDAP TMS reported a gross profit of EUR 24.4 million (USD 26.4 million) for the year ending December 31, 2023, reflecting a slight increase from the previous year. However, the gross profit margin declined due to inflationary pressures and investments in U.S. operations to support long-term revenue growth.
Recent achievements include the launch of the Focal One and strategic partnerships to expand its product reach. The company’s commitment to innovation and patient care makes it a significant player in the medical device industry.
EDAP TMS SA presented clinical data comparing Focal One HIFU versus surgery for treating deep infiltrating endometriosis at the 2024 AAGL Global Congress. The retrospective multicenter study analyzed 120 patients across two cohorts: 60 patients treated with HIFU and 60 with surgery. Results showed that HIFU therapy demonstrated significant advantages over surgical intervention, including fewer moderate and severe post-operative complications, shorter operating time, and reduced hospital stay. The company's ongoing Phase 3 trial shows promising progress, with over 85% of Sham treatment patients opting for HIFU therapy after symptoms returned.
EDAP TMS reported Q3 2024 worldwide revenue of EUR 13.1 million, up 11.6% year-over-year. HIFU revenue grew 48.2% to EUR 4.5 million, with 34% growth in U.S. Focal One procedures. The company sold three Focal One systems in Q3. Gross profit reached EUR 5.2 million with a 39.4% margin. Operating loss was EUR 5.8 million, and net loss was EUR 6.4 million. Notable developments include a new AI collaboration with Avenda Health, positive progress in BPH and endometriosis clinical trials, and CMS's 5.4% increase in Medicare Hospital Outpatient Focal One HIFU procedure payment for 2025.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has announced its participation in the upcoming 2024 Jefferies London Healthcare Conference. CEO Ryan Rhodes will present and conduct one-on-one investor meetings during the event, scheduled for November 19-21, 2024. The presentation is set for Tuesday, November 19, at 8:30-8:55 AM GMT at The Waldorf Hilton London. Both live and archived webcasts of the presentation will be available through the company's website's Investor section.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has scheduled its third quarter 2024 financial results release for November 7, 2024, before market open. The company will host a conference call and webcast at 8:30 AM EDT on the same day. CEO Ryan Rhodes, CFO Ken Mobeck, and CAO François Dietsch will lead the discussion. The conference call will be accessible via domestic (1-800-445-7795) and international (1-785-424-1699) dial-in numbers using passcode EDAP.
EDAP TMS SA (Nasdaq: EDAP) has announced the initiation of a Phase I/II study evaluating its Focal One® robotic high-intensity focused ultrasound (HIFU) technology for treating benign prostatic hyperplasia (BPH). The first patients have been treated in this study, which aims to explore a less invasive treatment option for BPH.
The study is designed in two parts: Part 1 will define optimal treatment parameters at two leading academic centers in France, while Part 2 will validate safety and efficacy across multiple centers. Dr. Harry Toledano, Head of Urology at Martigues Hospital, expressed enthusiasm about the potential of HIFU to improve BPH symptoms with minimal side effects.
EDAP's CEO, Ryan Rhodes, highlighted the significant need for less invasive BPH treatments and sees this as a logical expansion of their technology beyond prostate cancer applications. The company plans to initiate a BPH clinical study in the United States next year based on this foundational research.
EDAP TMS SA (Nasdaq: EDAP) and Avenda Health have launched the world's first AI-assisted Focal One® Robotic HIFU procedures for prostate cancer treatment. The collaboration integrates Avenda's FDA-cleared Unfold AI® technology with EDAP's Focal One robotic HIFU platform. Unfold AI creates 3D patient-specific cancer maps, enabling more precise tumor targeting and healthy tissue preservation.
The first AI-assisted procedures were successfully performed at UCLA School of Medicine. This integration aims to provide more tailored, patient-specific HIFU ablation for prostate cancer patients. The companies will present simulated procedures at the 2024 Joint Meeting of the Focal Therapy Society & Society of Urologic Robotic Surgeons in Washington, DC.
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. Ryan Rhodes, EDAP's CEO, will engage in a fireside chat and conduct one-on-one investor meetings.
Key details:
- Date: Tuesday, September 10th, 2024
- Time: 3:00-3:30 PM ET
- Location: Lotte New York Palace Hotel
EDAP TMS SA reported record Q2 2024 total worldwide revenue of EUR 15.8 million (USD 17.0 million), a 10.6% increase over Q2 2023. The company experienced strong U.S. Focal One® HIFU procedure growth of 63% year-over-year. Key highlights include:
- Five Focal One systems placed in Q2, including two at NCI-designated comprehensive cancer centers
- Strong year-over-year procedure growth indicating increasing adoption of robotic HIFU
- Appointment of new board member and strengthened European commercial leadership
- Presentation of final HIFI study results at AUA 2024, showing Focal One as effective as radical prostatectomy for localized prostate cancer
- Interim results from Phase 3 endometriosis study and approval to initiate Phase 1-2 BPH clinical trial
Despite revenue growth, the company reported an operating loss of EUR 6.1 million for Q2 2024, compared to EUR 4.2 million in Q2 2023, due to increased investments in commercial and R&D functions.
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, has announced it will release its financial results for the second quarter ended June 30, 2024, before markets open on Wednesday, August 28th, 2024. The company will host a conference call and webcast on the same day at 8:30am EDT.
The call will be conducted by Ryan Rhodes (CEO), Ken Mobeck (CFO), and François Dietsch (Chief Accounting Officer). Investors can join the call using the provided domestic and international dial-in numbers or through the webcast link.
EDAP TMS SA (Nasdaq: EDAP) announced that its robotic HIFU technology platform, Focal One, will be featured at the 41st World Congress of Endourology and Uro-Technology (WCET 2024) in Seoul, South Korea, from August 12-16, 2024. The event will showcase a semi-live Focal One clinical procedure conducted by Dr. Tarik Benidir from the University of Florida on August 15th at 5:00 pm (KST).
CEO Ryan Rhodes highlighted the increasing interest from urologists in using non-invasive HIFU technology for prostate cancer management. The company will provide hands-on Focal One simulations for attending urologists, demonstrating EDAP's significant presence at the conference and the growing trend in HIFU technology adoption.
FAQ
What is the current stock price of EDAP TMS SA (EDAP)?
What is the market cap of EDAP TMS SA (EDAP)?
What does EDAP TMS SA specialize in?
What are the main divisions of EDAP TMS SA?
What products are included in the HIFU division?
What is the function of the ESWL division?
What type of products does the Distribution division market?
What recent achievements has EDAP TMS SA accomplished?
How does EDAP TMS SA support its innovation?
What were the financial results for EDAP TMS SA in 2023?
How does EDAP TMS SA maintain its market position?
Who can be contacted for investor relations at EDAP TMS SA?
